Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966527 | 1.00 | GPR3 (0.33) | GPR3PLCG1MEN1KMT2ANOX1 | |
| SCHEMBL2918638 | 0.78 | GPR3 (0.36) | GPR3PLCG1MEN1KMT2ANOX1 | |
| SCHEMBL255968 | 0.71 | GPR3 (0.46) | GPR3PLCG1MEN1KMT2ANOX1 | |
| SCHEMBL520270 | 0.71 | PLCG1 (0.33) | GPR3PLCG1MEN1KMT2ANOX1 | |
| SCHEMBL9782263 | 0.68 | GPR3 (0.31) | GPR3PLCG1 | |
| SCHEMBL1162920 | 0.66 | — | — | |
| SCHEMBL30533792 | 0.62 | CA1 (0.47) | GPR3PLCG1MEN1KMT2ANOX1 | |
| SCHEMBL61667 | 0.62 | CA1 (0.47) | GPR3PLCG1MEN1KMT2ANOX1 | |
| SCHEMBL3543729 | 0.61 | TSHR (0.32) | — | |
| SCHEMBL255966 | 0.61 | GPR3 (0.46) | GPR3PLCG1MEN1KMT2ANOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655686-B2 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | claimed |
| EP-1670803-B1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | claimed |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | AUBERSON YVES | 2007-01-18 | — | — | US | claimed |
| EP-1670803-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | Novartis AG (CH) | 2006-06-21 | — | — | EP | claimed |
| WO-2005035535-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2005-04-21 | — | — | WO | claimed |
| US-7655686-B2 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| EP-1670803-B1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | AUBERSON YVES | 2007-01-18 | — | — | US | disclosed |
| EP-1670803-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | Novartis AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005035535-A1 | CERTAIN SUBSTITUTED SPIROCYCLIC LACTAMS AND USE THEREOF AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015781-A1 | Certain substituted spirocyclic lactams and use thereof as pharmaceuticals | STS, RPS6KA5, RPIA | GPR3 1352/4885PLCG1 1813/4885MEN1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.